Chapters

Transcript

Video

How do you interpret the reduction in associated overall mortality seen with alirocumab in the ODYSSEY Outcome Trial as compared to the lack of such findings—at least prior to results for the extension phase in FOURIER —for the evolocumab trial?

How do you interpret the reduction in associated overall mortality seen with alirocumab in the ODYSSEY Outcome Trial as compared to the lack of such findings—at least prior to results for the extension phase in FOURIER —for the evolocumab trial?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Robert Rosenson, MD

Robert Rosenson, MD

Professor of Medicine (Cardiology)
Mount Sinai Icahn School of Medicine
Director, Cardiometabolics Unit
Mount Sinai Heart Institute
New York, NY